Dashboard
Manage Tickers

AMRX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-signs-of-stability
JP Morgan Shows Most Interest In Teva, Org...
09/06/2024 17:46:07

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...

jp-morgan-upgrades-amneal-pharmaceuticals-to-neutral-announces-9-price-target
JP Morgan Upgrades Amneal Pharmaceuticals ...
09/06/2024 12:10:00

JP Morgan analyst Chris Schott upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) from Underweight to Neutral and announces $9 pr...

amneal-and-shilpa-receive-fda-approval-for-boruzu-ready-to-use-bortezomib-injection-for-multiple-myeloma-and-mantle-cell-lymphoma-expected-launch-in-q2-2025
Amneal And Shilpa Receive FDA Approval For...
09/05/2024 20:13:02

amneal-announces-fda-approval-for-propofol-injectable-emulsion-single-dose-vials
Amneal Announces FDA Approval For Propofol...
08/20/2024 12:03:54

barclays-maintains-overweight-on-amneal-pharmaceuticals-raises-price-target-to-10
Barclays Maintains Overweight on Amneal Ph...
08/13/2024 12:45:47

Barclays analyst Balaji Prasad maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...

truist-securities-maintains-buy-on-amneal-pharmaceuticals-raises-price-target-to-10
Truist Securities Maintains Buy on Amneal ...
08/12/2024 12:50:12

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target...

amneal-expects-2024-adjusted-eps-of-057-063-versus-prior-guidance-of-053-063-and-consensus-of-061
Amneal Expects 2024 Adjusted EPS Of $0.57-...
08/09/2024 10:10:26

amneal-expects-2024-revenues-of-270b-280b-versus-prior-guidance-of-255b-265b-and-consensus-of-2646b
Amneal Expects 2024 Revenues Of $2.70B-$2....
08/09/2024 10:09:22

Raising Full Year 2024 GuidanceThe Company is raising its previously provided full year 2024 guidance. Updated GuidancePrior Gu...

amneal-pharmaceuticals-q2-2024-adj-eps-016-beats-014-estimate-sales-701780m-beat-658140m-estimate
Amneal Pharmaceuticals Q2 2024 Adj. EPS $0...
08/09/2024 10:07:13

amneal-receives-fda-approval-for-ipx203-for-parkinsons-disease-to-be-launched-as-crexont-extended-release-capsules
Amneal Receives FDA Approval for IPX203 Fo...
08/07/2024 21:20:48

Delivers more "Good On" time with less frequent dosing compared to Immediate Release CD/LDUnderscores Amneal's lead...

amneal-pharmaceuticals-receives-fda-approval-for-new-potassium-phosphates-iv-infusion-bag-first-preservative-free-single-dose-presentation-third-505b2-injectable-added-this-year-launching-in-q3
Amneal Pharmaceuticals Receives FDA Approv...
07/29/2024 20:25:58

amneal-pharmaceuticals-launches-focinvez-ready-to-use-injectable-anti-nausea-agent-for-chemotherapy-second-injectable-rtu-product-launched-in-2024-single-dose-vial-free-of-polysorbate-80-no-reconstitution-required
Amneal Pharmaceuticals Launches Focinvez, ...
07/09/2024 20:24:17

kashiv-biosciences-enters-into-exclusive-licensing-agreement-with-amneal-for-commercialization-of-a-proposed-biosimilar-to-xolair
Kashiv BioSciences Enters Into Exclusive L...
07/01/2024 12:02:59

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®)ADL018 is Kashiv's lead p...

Core News & Articles
Reported Monday June 10, 2024 "Amneal, U.S...
06/11/2024 14:40:07

https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...

amneal-expands-broad-injectables-portfolio-with-the-addition-of-six-new-product-launches
Amneal Expands Broad Injectables Portfolio...
06/05/2024 12:14:13

Amneal's Q2 2024 injectable product launches: Product launchDosage formASHP drug shortage1PEMRYDI RTU®VialNo2Atropine sulfa...

amneal-has-begun-supplying-otc-naloxone-hydrochloride-nasal-spray-to-us-retail-pharmacies-and-the-state-of-california
Amneal Has Begun Supplying OTC Naloxone Hy...
05/22/2024 20:32:47

Significantly expanding access to affordable, life-saving opioid overdose rescue medicineEntered distribution agreement with Ca...

assessing-amneal-pharmaceuticals-insights-from-4-financial-analysts
Assessing Amneal Pharmaceuticals: Insights...
05/06/2024 19:00:55

goldman-sachs-maintains-buy-on-amneal-pharmaceuticals-raises-price-target-to-8
Goldman Sachs Maintains Buy on Amneal Phar...
05/06/2024 15:15:42

Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...

truist-securities-reiterates-buy-on-amneal-pharmaceuticals-raises-price-target-to-9
Truist Securities Reiterates Buy on Amneal...
05/06/2024 12:32:09

Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price targe...

generic-drugmaker-amneal-announces-over-270m-in-us-opioid-lawsuit-settlement
Generic Drugmaker Amneal Announces Over $2...
05/03/2024 18:43:45

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 ear...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION